[ad_1]
Tevogen Bioa clinical stage biotechnology company developing cell and gene therapies in virology, oncology, and neurology, today announced it has completed a strategic investment by HMP Partners of New Jersey, a life sciences investment firm managed by medical doctors.
Tevogen’s next generation precision T cell platform is designed to provide increased target specificity to eliminate malignant and viral infected cells, while allowing healthy cells to remain intact. Multiple targets are selected in advance with the goal of overcoming mutational capacity of cancer cells and viruses. The Potentially disruptive technology is designed to allow development of unmodified T cell therapeutics from a single donor to treat hundreds of patients sharing the same human leukocyte antigen (HLA) type, without the need for specialized medical facilities. Tevogen believes that this “off-the- shelf” convenience will make it possible to develop T cell therapies with greater convenience, unprecedented speed, and at a much lower cost than currently available platforms, such as CAR-T. This creates an opportunity to dramatically improve health outcomes for large patient populations battling common life-threatening cancers and viral infections.
Tevogen intends to use the net proceeds from the investment to expedite expansion of Tevogen’s development pipeline and to support accelerated development of Tevogen’s lead product candidate. The candidate, TVGN-489, is a COVID-19-specific CD8+ T lymphocyte (CTL) investigational product , currently in proof-of-concept trial that recently passed its midway point. TVGN-489 is a highly purified product designed to detect proteins that are spread across the entire viral genome and found across COVID-19 variants. In addition, TVGN-489 is designed not to be susceptible to spike mutations as the targets are selected from the entire genome.
Tevogen believes that therapeutic approaches to date have not harnessed CD8+ Cytotoxic T-Lymphocytes, also known as killer T cells to their full potential for clinical application. Currently…
Full story available on Benzinga.com
[ad_2]
Source link
